Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high

This company has busily deployed cash over the past six months while growing at a phenomenal pace.

| More on:
Happy healthcare workers in a labs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One ASX healthcare stock is clocking a new record price today while the S&P/ASX 200 Index (ASX: XJO) struggles to keep its head above water.

The Aussie share market is flailing this afternoon after the Australian Bureau of Statistics (ABS) published March inflation figures.

To the absolute displeasure of Australian equity investors, the monthly consumer price index rose 1.0% in the March-ending quarter, reflecting an annual rate of 3.6%. Economists were expecting 3.5%. The concern of a prolonged interest rate pause is dampening much of the market today.

But breaking through the bemoaning bout is an ASX healthcare stock on a roll. Factoring in today's 4% gain, this little beauty is up 73.9% in a six-month timespan.

I'm talking about none other than Telix Pharmaceuticals Ltd (ASX: TLX).

Let's delve deeper into this record-setter.

Why are investors buying up this ASX healthcare stock?

Investors have acquired a taste for Telix Pharmaceuticals over the past six months.

Momentum began building in the backend of 2023 when the company completed the acquisition of Lightpoint Medical and put forward its intentions to take over QSAM Biosciences. The two purchases expanded upon Telix's radiopharmaceutical ensemble.

The ASX healthcare stock didn't stop there.

This year, the company acquired IsoTherapeutics and ARTMS, a US drug manufacturer and an Isotope producer. It's evidence that Telix is unafraid to put its cash to work, using some of its $123 million cash stash.

Among all the acquisitions, the core business — underpinned by Illucix — keeps humming along.

The company released its first quarter update on 17 April, showing further growth for its prostrate cancer imaging agent. Unaudited total revenue grew 18% to US$114.9 million, driven mainly by sales in the United States.

Topping it off, the ASX healthcare stock reaffirmed guidance of US$445 million to US$465 million in revenue for FY2024.

What's next?

While Telix is generating revenue from its prostrate imaging agent, it's also exploring other cancer-targeting agents.

The United States Food and Drug Administration granted the company 'fast track designation' last week for TLX101-CDx glioma (brain cancer) imaging. Renal imaging is also in Telix's product pipeline for future growth potential.

Monash Investors' Shane Fitzgerald has described this ASX healthcare stock as one that could go 'on to become the next CSL in Australia'.

For now, it's a high-flying single-product company with a $4.9 billion market capitalisation.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »